Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-5700 in Dengue-Seropositive Adults
NCT02887482Phase 1Completed
- Sponsor
- GeneOne Life Science, Inc.
- Start
- Aug 2016
- Primary completion
- Oct 2017
- Modality
- Prophylactic Vaccines, Antisense DNA, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Zika virus infection comparing Placebo with GLS-5700 (2 arms). Primary endpoints: Mean change from baseline in safety laboratory measures, Incidence of solicited adverse events after vaccination and 2 more. Started Aug 2016; status: completed.
02
Drugs
GLS-5700
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT02887482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02887482.